{"version":"1.0","type":"rich","provider_name":"techandbusiness.org","provider_url":"https://techandbusiness.org","title":"Local tumor C3, not blood C3, drives immunotherapy response in Nagoya study","author_name":"techandbusiness.org · Tech & Business","thumbnail_url":"https://www.sciencedaily.com/images/1920/nk-immune-cells-destroying-cancer.webp","width":600,"height":400,"html":"<blockquote class=\"tb-newswire-embed\" style=\"max-width:600px;border-left:3px solid #22d3ee;padding:12px 16px;margin:0;font-family:-apple-system,system-ui,sans-serif;background:#09090b;border-radius:0 8px 8px 0;\">\n      <p style=\"margin:0 0 8px;font-size:10px;font-weight:600;letter-spacing:0.1em;color:#71717a;\">techandbusiness.org · Tech & Business</p>\n      <p style=\"margin:0 0 8px;font-size:18px;font-weight:700;line-height:1.3;color:#fff;\"><a href=\"https://techandbusiness.org/newswire/fkAzErBgCGY4jb2YdOwdbN\" style=\"color:#fff;text-decoration:none;\">Local tumor C3, not blood C3, drives immunotherapy response in Nagoya study</a></p>\n      <p style=\"margin:0;font-size:14px;color:#a1a1aa;line-height:1.5;\">ScienceDaily reported that Nagoya University scientists found complement protein C3 improves cancer immunotherapy only when it is produced locally in tumor tissue, not when it arrives through the bloodstream, according to a Nature Communications study....</p>\n    </blockquote>"}